Consequently, the elevated levels of miR-19a-3p observed in the serum of patients with metastatic HER2 + breast cancer may partly result from effective tumor cell killing by NK cell-mediated ADCC, reflecting a positive response to trastuzumab-based therapy associated with a favorable prognosis. This evidence concerns the gene ERBB2 and breast cancer.